Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    Alzheimer's | Open Studies | United States, Utah
Show Display Options
RSS Create an RSS feed from your search for:
Alzheimer's | Open Studies | United States, Utah
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Condition: Alzheimer's Disease
Interventions: Drug: SUVN-502;   Drug: Placebo
2 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Alzheimer's Disease
Intervention: Drug: AVP-786
3 Recruiting An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease
Condition: Alzheimer´s Disease
Interventions: Drug: LY3314814;   Drug: Placebo
4 Recruiting A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia
Condition: Alzheimer's Disease
Interventions: Drug: LY3314814;   Drug: Placebo
5 Recruiting Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Azeliragon;   Drug: Placebo
6 Recruiting Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
Condition: Alzheimer's Disease
Interventions: Drug: RVT-101;   Drug: Placebo
7 Recruiting A Study of Gantenerumab in Patients With Mild Alzheimer Disease
Condition: Alzheimer's Disease
Interventions: Drug: florbetapir;   Drug: gantenerumab;   Drug: placebo
8 Recruiting Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
9 Recruiting Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
10 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
11 Recruiting Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: ALZT-OP1a;   Drug: ALZT-OP1b;   Other: Placebo ALZT-OP1a;   Other: Placebo ALZT-OP1b
12 Recruiting CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Interventions: Drug: Crenezumab;   Drug: Placebo
13 Recruiting A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Conditions: Healthy;   Alzheimer's Disease;   Mild Cognitive Impairment
Interventions: Drug: LY2599666;   Drug: Solanezumab;   Drug: Placebo SC;   Drug: Placebo IV
14 Recruiting Implications for Management of PET Amyloid Classification Technology
Conditions: Mild Cognitive Impairment;   Dementia;   Alzheimer's Disease
Intervention: Drug: [18F]Flutemetamol
15 Recruiting A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
Condition: Alzheimer Disease
Interventions: Biological: LY3002813;   Drug: Placebo
16 Recruiting Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Condition: Dementia
Intervention: Procedure: FDG-PET brain scan
17 Recruiting Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Condition: Breast Cancer
Intervention: Drug: FDG-PET, [18F]Flutemetamol
18 Recruiting Cognitive Training and Practice Effects in MCI
Condition: Mild Cognitive Impairment
Intervention: Behavioral: computerized cognitive exercises

Indicates status has not been verified in more than two years